The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What's going on?

The dip in Pro Medicus shares is accompanied by a sector-wide sell-off.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Pro Medicus Limited (ASX: PME) have had a poor run these past few days after falling off a high of $62.48 on 30 November.

There's been no market-sensitive information out of the Pro Medicus camp in this time. But that hasn't stopped investors selling off shares violently. The company opened Monday's session at $55.93 after pre-market trading.

A female health professional has a wide-eyed shocked expression on her face, even behind the face mask.

Image source: Getty Images

What's up with Pro Medicus shares?

Despite the recent weakness, shares in the health imaging IT provider were a standout performer in November. They closed out the month 17% in the green – well ahead of most healthcare majors.

However, the dip in Pro Medicus shares is accompanied by a sector-wide sell-off. This sell-off has been in situ since we rolled into December.

For instance, the S&P/ASX 200 Health Care Index (XHJ) has slipped 5% since the end of November, and shows no sign of slowing from the open today.

Concern around the Omicron COVID-19 variant and frothy share markets around the world has many investors taking risk off the table and seeking more defensive positions in safer assets, according to recent analysis from Goldman Sachs and JP Morgan.

Goldman has even lowered its 2022 US GDP forecasts from 4.2% to 3.8%, citing risks and potential impacts of the new strain, according to reporting from Bloomberg Intelligence.

This activity appears to have boded poorly for ASX health care shares, Pro Medicus included.

Although, the team at investment bank Citi reckons the pullback in the company's share price is warranted.

The firm rates Pro Medicus a sell at $45/share and reckons that investors could be overly optimistic in their growth projections for the company.

Citi notes the presence of many substitute products from Pro Medicus' competitors that could originate in future. This poses a threat to the company's profits and could compress its margins going forward, the broker says.

In the absence of any price-sensitive information out of the company's camp lately, it appears that weakness in the wider sector has spilled over into names like Pro Medicus as a negative catalyst to its share price.

Pro Medicus share price snapshot

In the past 12 months the Pro Medicus share price has climbed more than 90%. Pro Medicus shares have rallied 67% this year to date.

However, they have taken a backward step in the last month and are almost 7% in the red. The Pro Medicus share price has fallen 6.65% in just the last week of trading.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended SDI Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

smiling health care workers in a medical setting
Share Market News

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX small-cap healthcare stock could rocket more than 50%: Morgans

Share price weakness could present an opportunity.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Guess which ASX 300 stock was given a big boost from the US FDA

This healthcare stock has made a positive announcement today.

Read more »